Project Grant R21NS143203
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$461K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research to investigate the role of the deubiquitylation pathway in TDP-43 pathology associated with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The $460,625 award, with a project period from June 7, 2025 to May 31, 2027, will enable the University...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $251,250.00 to the University of Massachusetts Medical School (UMass Medical) to investigate the role of TDP-43 dysfunction and its impact on neuroimmune processes in models of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award period runs from April...
This Project Grant award of $638,682 from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), supports research to investigate the role of liquid-liquid phase separation (LLPS) of the TDP-43 protein and its interactions with mitochondria in neurodegenerative diseases. The research aims to systematically examine how LLPS regulates TDP-43 localization to mitochondria, and how this contributes to TDP-43-induced mitochondrial dysfunction and neuronal loss, using...
This Project Grant award of $374,349 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create a mouse model that accurately recapitulates the human disease spectrum by incorporating an acetylation-mimicking...
This federal Project Grant award, valued at $129,717.00 and awarded on January 20, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of neutrophil heterogeneity and molecular mechanisms in driving amyotrophic lateral sclerosis (ALS). The research aims to identify subpopulations of neutrophils and associated mechanisms...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Case Western Reserve University provides $442,750 to develop synthetic replicas of TDP-43 protein filaments associated with frontotemporal dementia and amyotrophic lateral sclerosis. The goal is to establish in vitro conditions for generating amyloid fibrils with structures identical to brain-derived TDP-43 filaments, which would enable mechanistic studies on disease-relevant aggregation pathways...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded Aquinnah Pharmaceuticals, Inc. a $1,499,212 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to develop a novel oral brain penetrant therapeutic for amyotrophic lateral sclerosis (ALS). The project aims to manufacture the therapeutic candidate, conduct IND-enabling studies, and engage in a pre-IND meeting with the FDA. The goal is to create the first effective...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to investigate the role of proton-mediated signaling at the neuromuscular junction in amyotrophic lateral sclerosis (ALS) models. The $387,525 award to the Board of Regents of the Nevada System of Higher Education, operating through the University of Nevada, Reno, will...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to identify the mechanisms by which the protein TDP-43 impacts muscle structure and function in amyotrophic lateral sclerosis (ALS) and related neuromuscular disorders. The $461,900 award to Pennsylvania State University's Milton S. Hershey Medical Center, with a sub-award to Thomas Jefferson University, will fund a 2-year study to map TDP-43 dependent changes in newly synthesized...